Incyte raises sales guidance while acquisition accounting drives a quarterly loss
Incyte ($INCY) raised its 2026 product-sales outlook to $5.21–$5.30 billion from $5.13–$5.26 billion following a 14% increase in third-quarter 2026 total revenue to $1.56 billion. Product sales reached $1.32 billion. Opzelura grew 36% to $255 million and the hematology and oncology portfolio rose 38% to $235 million, strengthening businesses beyond Jakafi, whose sales increased 4% to $827 million. The company nevertheless recorded a $784.8 million net loss, mainly reflecting a $1.23 billion acqu
0